Un estudio publicado en la revista Science analiza la respuesta inmunitaria del SARS-CoV-2 varios meses después de la infección. Los resultados muestran indicios de una inmunidad protectora robusta ...
Read moreA complete integrated freeze-drying system designed for high value anticancer products consisting of a reduced foot-print freeze dryer with an innovative loading/unloading system, integrating a steam-...
Read moreMestrelab Research acaba de cumplir 16 años en el mercado y tienen ventas en 118 países.
Read morePharmaceutical company Almirall, a CataloniaBio & HealthTech member, and biotechnology firm Tyris Therapeutics have announced a new alliance to develop non-viral gene therapies to treat minority derma...
Read moreThe European Medicines Agency Network Strategy to 2025 was detailed just last week during the 20th Regulatory Affairs and Pharmacovigilance conference.
Read moreMinoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces topline...
Read moreLa Ponencia de Alertas y Planes de Preparación y Respuesta , órgano de gestión y seguimiento del Sistema Nacional de Alerta Precoz y Respuesta Rápida dependiente de la Comisión de Salud Pública,...
Read moreDesde el inicio de la pandemia de Covid-19 ha sido frecuente escuchar comentarios sobre el temor de que el SARS-CoV-2 mutara hacia una forma más agresiva. En la mente de muchas personas se visualizab...
Read moreSon los proyectos de Luis Enjuanes, Isabel Sola y Sonia Zúñiga, en el CNB-CSIC, de Mariano Esteban y Juan García Arriaza, en el CNB-CSIC, y de Vicente Larraga, en el CIB-CSIC
Read moreCancer is the second biggest cause of death throughout the world today. Every year 9.6 million people die from it, 65% of them in low- and medium-income countries. Spain shows a similar trend to other...
Read moreNew drug innovation remained strong in 2020. The total of 53 drugs approved represented the second-highest number of approvals in more than two decades, a positive indicator of productivity in the pha...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today an...
Read more